THE COMBATING ANTIBIOTIC RESISTANT BACTERIA BIOPHARMACEUTICAL ACCELERATOR ‘CARB-X' (360G-Wellcome-208608_Z_17_Z)
The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) brings together leaders from industry, philanthropy, government and academia. It is a collaboration between the Biomedical Advanced Research and Development Authority (“BARDA”), the National Institute of Allergy and Infectious Diseases (“NIAID”), both within the US Department of Health and Human Services, and the Trustees of Boston University (“BU”). The international partnership will support a suite of products through early preclinical development. CARB-X aims to get products to a stage where private or public investors can then take them forward.
|Approval Committee||Internal Decision Panel|
|Grant Programme: Title||Discretionary award – DRI|
|Lead Applicant||Prof Kevin Outterson|
|Planned Dates: End Date||2021-07-31T00:00:00+00:00|
|Planned Dates: Start Date||2017-04-01T00:00:00+00:00|
|Recipient Org: Country||United States|